Home › Research › Inflammation and the immune system
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients
Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R et al.. The journal of prevention of Alzheimer's disease, 2020-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Here we describe results of a Phase 2a study of a promising new drug candidate that significantly reversed all measured biomarkers of Alzheimer's disease, neurodegeneration and neuroinflammation. The result is reduced tau hyperphosphorylation and neuroinflammation, with multiple functional improvements demonstrated in transgenic mice and postmortem Alzheimer's disease brain. Results Consistent with the drug's mechanism of action and preclinical data, PTI-125 reduced cerebrospinal fluid biomarkers of Alzheimer's disease pathology, neurodegeneration and neuroinflammation from baseline to Day 28. Aβ42 increased slightly - a desirable result because low Aβ42 indicates Alzheimer's disease. As a result, filamin A linkages with α7-nicotinic acetylcholine receptor and toll-like receptor 4, and Aβ42 complexes with α7-nicotinic acetylcholine receptor and CD14, were all significantly reduced by PTI-125. Conclusions PTI-125 significantly reduced biomarkers of Alzheimer's disease pathology, neurodegeneration, and neuroinflammation in both cerebrospinal fluid and plasma.
What this study adds
Evidence grade: High
This is a trial of 13 participants. In a Phase 2a study, the experimental drug PTI-125 reduced cerebrospinal fluid biomarkers of Alzheimer's disease pathology, neurodegeneration and neuroinflammation from baseline to Day 28, and the authors report similar reductions in plasma. Reported effect size: decreased by 20%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, H. Y., Pei, Z., Lee, K. C., Lopez-Brignoni, E., Nikolov, B., Crowley, C. A., et al. (2020). PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2020.6
Vancouver
Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, et al. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients. The journal of prevention of Alzheimer's disease. 2020. doi:10.14283/jpad.2020.6. PMID: 32920628.
BibTeX
@article{wang2020-32920628,
author = {Wang, H. Y. and Pei, Z. and Lee, K. C. and Lopez-Brignoni, E. and Nikolov, B. and Crowley, C. A. and Marsman, M. R. and Barbier, R. and others},
title = {{PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2020},
doi = {10.14283/jpad.2020.6},
pmid = {32920628},
url = {https://doi.org/10.14283/jpad.2020.6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Here we describe results of a Phase 2a study of a promising new drug candidate that significantly reversed all measured biomarkers of Alzheimer's disease, neurodegeneration and neuroinflammation.
- The result is reduced tau hyperphosphorylation and neuroinflammation, with multiple functional improvements demonstrated in transgenic mice and postmortem Alzheimer's disease brain.
- Results Consistent with the drug's mechanism of action and preclinical data, PTI-125 reduced cerebrospinal fluid biomarkers of Alzheimer's disease pathology, neurodegeneration and neuroinflammation from baseline to Day 28.
- Aβ42 increased slightly - a desirable result because low Aβ42 indicates Alzheimer's disease.
- As a result, filamin A linkages with α7-nicotinic acetylcholine receptor and toll-like receptor 4, and Aβ42 complexes with α7-nicotinic acetylcholine receptor and CD14, were all significantly reduced by PTI-125.
Why it matters
In a Phase 2a study, the experimental drug PTI-125 reduced cerebrospinal fluid biomarkers of Alzheimer's disease pathology, neurodegeneration and neuroinflammation from baseline to Day 28, and the authors report similar reductions in plasma. These are short-term biomarker changes, so they mark a drug candidate for further testing rather than proof that it helps patients' symptoms.
Study details
- Study designopen-label trial
- Participants13
- Effect sizedecreased by 20%
- Evidence strengthHigh
How this study scored 55/100
Published in a peer-reviewed journal, and it is a mid-stage phase 2 trial. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 8 / 12 | A mid-stage phase 2 trial (from PubMed type “Clinical Trial, Phase II”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 13 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 45 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.6 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 2 / 6 | Cited 2.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 26 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Lindsay H. Burns: h-index 30 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | City University of New York: institution h-index 646 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32920628) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.14283/jpad.2020.6
- PubMed: 32920628
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Inflammation and the immune system from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.